Juno Therapeutics Inc (NASDAQ:JUNO) shares are trading down 1.29% to 51.16 this morning after the company posted Q3 earnings yesterday after marking close. The company posted non-GAAP revenues of $1.6 million for the quarter, much lower than analysts’ estimates of $6.51 million. Non-GAAP losses per share were ($0.53), wider than analysts’ estimates of ($0.41). Investors are concerned about the much higher than predicted cash burn of $206.4 million year-to-date, compared to the company’s estimate of $150 million for the entire year. Juno has made headlines recently for its successful trials of cancer-fighting immunotherapy treatments. According to the 3 analysts polled by TipRanks in the last 3 months, 2 are bullish on the stock while 1 remains on the sidelines. The average 12-month price target for the stock is $71.50, marking a 38% potential upside from where shares last closed.
Capstone Turbine Corporation (NASDAQ:CPST) shares spiked 7.17% in pre-market trading this morning after announcing plans to fulfill an order for two C100 micro turbines, which will provide CHP (combined heat and power) in Hungary. The order was secured by the company’s local distributor, Regale Energy Zrt. The order comes as a win for both the company and the country of Hungary, as the micro turbines will help the country meet its 2020 renewable energy goals. Jim Crouse, Executive Vice President of Sales and Marketing for Capstone stated, “Capstone is encouraged to see our global CHP markets continue to grow globally, especially in countries that are seeking energy independence.” According to TipRanks’ statistics, out of the 2 analysts who have rated CPST in the last 3 months, 1 is bullish while the other remains on the sidelines. The average 12-month price target for CPST is $9.00, marking a 222% upside from where shares last closed.
Westport Innovations Inc. (USA) (NASDAQ:WPRT) shares are trading down 6.55% to $3.14 this morning following its release of disappointing Q3 earnings yesterday after market-close. The company posted revenues of $22.3 million and a loss of ($0.58) per share. The figures missed analysts revenue and earnings expectations of $27.5 million and ($0.25), respectively. According to TipRanks’ statistics, out of the 2 analysts who have rated WPRT in the last 3 months, both remain on the sidelines. The average 12-month price target is $5.40, marking a 60.71% upside from where shares last closed.
Horizon Pharma PLC (NASDAQ:HZNP) shares fell 17.78%% to $18.40 this morning following a lawsuit from Express Scripts. The company sued Horizon Pharma for $140 million and alleged that they did not fulfill obligations regarding contracted rebates. They also cut ties with Linden Care, after discovering their preference to dispense HZNP drugs. Express Scripts is currently investigating other pharmacies who sell most of their products from one particular drug company. The company fired back, stating “We are still reviewing the allegations in the complaint but we believe the claims are without merit and we intend to vigorously defend ourselves.” According to TipRanks’ statistics, out of the 6 analysts who have rated HZNP in the last 3 months, 5 give the stock a Buy rating, while 1 remains on the sidelines. The average 12-month price target for HZNP is $41.80, marking an 87% upside from where shares last closed.